Introduction: in order to avoid "salami slice" article the authors must explain why they did not publish this results in their previous paper where they presented efficacy analysis:" A previous randomized clinical trial (RCT) investigated the effectiveness of exposure-based Internet-CBT for adolescents with IBS compared with a waitlist control" Methods: "Participants were recruited from the whole of Sweden via primary, secondary and tertiary care clinics reached through news media and advertising. To be included, the participants needed a confirmed diagnosis of IBS by their treating physician and to be aged ≥13 and <18 years old." Please explain which diagnostic criteria have been used? Rome III Rome IV? Do you have IBS subgroup data? Please explain with more details randomisation technique "Participants were randomized at baseline to either an exposurebased Internet-CBT or a waitlist." Do you have data regarding power analysis? Instruments: I agree with the authors regarding the use of general QoL instrument "Paediatric Quality-of-Life Inventory TM 8 Version 4.0", but I'm missing some disease-specific QoL such as IBS QOL or similar? Please explain Results: the author's employed appropriate statistics. I appreciate informative tables Conclusions are justified by results.
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GENERAL COMMENTS
The justification for using the clinical outcome (PedsQoL score) over an economic outcome (QALYs) based on statsitical signficance is incorrect. Please see the Irrelevance of Inference (Klaxton 1999) which provides the theoretical basis for cost effectiveness analysis. Please use a cost utility analysis to present the primary analysis with the prevailing Swedish cost per QALY thresholds.
The public sector perspective is stated on page 6 line 18-19 as includng direct medical costs and indirect costs such as productivity losses. This is a societal perspective. Keywords: please put in alphabetical order All keywords are now in alphabetical order. Please see page 1.
Introduction: in order to avoid "salami slice" article the authors must explain why they did not publish this results in their previous paper where they presented efficacy analysis:" A previous randomized clinical trial (RCT) investigated the effectiveness of exposure-based Internet-CBT for adolescents with IBS compared with a waitlist control" This is a very relevant observation which needs clarification. A health economic evaluation was planned from the very start but the authors did not think that it would be possible to include them in the main manuscript, given the complexity of such analyses and the length required to report them.
Methods: "Participants were recruited from the whole of Sweden via primary, secondary and tertiary care clinics reached through news media and advertising. To be included, the participants needed a confirmed diagnosis of IBS by their treating physician and to be aged ≥13 and <18 years old." Please explain which diagnostic criteria have been used? Rome III Rome IV? Adolescents had to have a confirmed diagnosis of IBS according to the Rome III criteria to be included in the study. This information has been added in the text, see page 5, lines 16-17:
"To be included, the participants needed a confirmed diagnosis of IBS according to the Rome III criteria 17…" Please explain with more details randomisation technique "Participants were randomized at baseline to either an exposure-based Internet-CBT or a waitlist."
We have extracted some more information about the randomization procedure from the efficacy study. Please see below. This information has also been added to the method section "Interventions", page 6, lines 4-6.
After completing the pretreatment assessment, participants were consecutively randomized to either exposure-based Internet-CBT or a waitlist. The randomization was conducted by an independent researcher, who received lists with anonymous study ID numbers and used a random number service (www.random.org) to allocate participants, thus ensuring concealment of allocation. From November 2013 to August 2015, 101 participants were included and randomized, 47 to Internet-CBT and 54 to the waitlist.
Do you have data regarding power analysis?
A power analysis was conducted for the efficacy study and is available in the published paper by Bonnert et al, 2017 1. To obtain a power of 80% to detect a between-group effect size of d =0.6 on the primary outcome measure GSRS-IBS (based on a previous feasibility study conducted by the authors), the authors planned to recruit at least 100 participants. There was, however, no power analysis done for the cost effectiveness evaluation.
Instruments: I agree with the authors regarding the use of general QoL instrument "Paediatric Qualityof-Life Inventory TM 8 Version 4.0", but I'm missing some disease-specific QoL such as IBS QOL or similar? Please explain In the trial, one measure of disease specific QoL was indeed included, the 9-item PedsQL Gastro parent form. This instrument was used by parents to assess their child's gastrointestinal symptoms, and the results are reported in table 2 of the efficacy study by Bonnert et al, 2017 1, along with a few other specific measures. Nevertheless, the 23-item Pediatric Quality-of-Life Inventory (PedsQL) was chosen for the economic evaluation for three reasons. First, there was a child version completed by adolescents, who we wanted to use as main reporters; second this instrument could be mapped to a preference-based multi-attribute utility instrument, namely, the Child Health Utility-9 Dimensions (CHU9D), which would allow us to estimate quality adjusted life years; third, in case the mapping were not possible, the PedsQL would allow for comparison with other studies in the child health field using the same measure.
We have inserted a printscreen of the table with the data on PedsQL Gastro reported by parents from the efficacy study below for your reference.
Please see printscreen in the file attached. The justification for using the clinical outcome (PedsQoL score) over an economic outcome (QALYs) based on statistical significance is incorrect. Please see the Irrelevance of Inference (Klaxton 1999) which provides the theoretical basis for cost effectiveness analysis. Please use a cost utility analysis to present the primary analysis with the prevailing Swedish cost per QALY thresholds. Thank you for your comment. We have addressed this issue throughout the whole manuscript. A cost utility analysis using the mapped utilities to generate QALYs is now the primary analysis, with a cost effectiveness analysis using the PedsQL scores as a secondary analysis. Please see the changes using track changes throughout the manuscript.
The public sector perspective is stated on page 6 line 18-19 as including direct medical costs and indirect costs such as productivity losses. This is a societal perspective. This is correct. We acknowledge the mistake and have made appropriate changes in the text. 11. Results page 12 line 12 the correct probability of cost effectiveness should be the proportion of replicates falling below the Swedish WTP threshold, not the proportion in the north eastern quadrant of the cost effectiveness plane.
12. Figure 1 Please leave your comments for the authors below I thank the authors for positively responding to all the reviewer comments. They now present a cost per QALY base case which enhances the interpretation and generalisability of their findings. There are, however, many questions about the data and the analysis which need to be clarified. Table 4 refers to the bootstrapped difference in costs adjusted for baseline costs. The estimate reported on page 13, line 1 and in Table 3 , ie. 163.81 USD is the difference in costs between groups estimated by generalized linear models before bootstrapping. Multiple imputation was used to calculate both estimates. Both the abstract and Table 4 report the bootstrapped cost difference of 170.24 USD. Table 3 and the results section (page 12, lines 13-14) report both estimates before and after bootstrapping.
2. Abstract Page 2 Results line 17 remove the statement 'non-significant' the study was not powered to reliably detect a difference in QALYs.
The statement has been removed from the abstract on page 2.
3. Abstract Page 2 Results line 20 the statement that Internet-CBT is dominant is incorrect, the additional QALYs were gained at a higher cost. This terminology was incorrect by mistake, for which we apologize. This statement has been replaced by "Internet-CBT yielded ICER of $54,916/QALY gained and a probability of cost-effectiveness of 74% given the Swedish willingness-to-pay threshold." On page 2, lines 23-24.
4. Abstract Page 2 Results please add a statement about the cost per QALY (which I calculate as 288.60 divided by 0.005 = US$57,720 and the probability of cost effectiveness using the Swedish WTP.
A statement was added to the abstract, page 2, lines 23-24, as follows: "Internet-CBT yielded ICER of $54,916/QALY gained and a probability of cost-effectiveness of 74% given the Swedish willingnessto-pay threshold" 5. Methods page 8 line 17 please provide the mapping algorithm. Please justify why an area under the curve approach to measuring QALY gain was not used.
We have used a new mapping algorithm that maps PedsQL scores onto EQ-5D-3L utilities. This algorithm is based on data from children aged 11-15 years and includes all the dimensions of the PedsQL (contrary to the mapping algorithm used previously). The mapping algorithm was included in the method section, page 9, lines 7-15, along with a description of the methodology used, page 8-9. We have now used an area under the curve approach to calculate QALYs over the trial period and reported it accordingly in the manuscript.
6. Methods page 10 line 12 please clarify what is meant by using all available data.
We apologize for the lack of clarity, this has been properly changed to "complete cases" where appropriate, referring to the analysis of the cases with complete cost and QALY data at the 10 week follow-up. Please find in text on page 11, lines 13-14. All numbers in table 3, pages 24-25, have been updated following the use of the new mapping algorithm and new imputation of dataset. However, the reason to why the numbers did not add up previously was because the estimate for total healthcare costs was including the intervention cost of 178.36. This cost was not, however, doubled/repeated in the final estimate of total societal cost. We have now reported the total healthcare cost for each group and the incremental estimate (mean = 9.76 (-23.44 -87.66) excluding the intervention cost to avoid confusion. Following the new analysis, the new calculation is now: 178.36 (intervention) + 9.76 (total healthcare) -4.84 (total prod loss school) -122.88 (total prod loss paid work) + 0.55 (tot prod loss unpaid work) = 60.95 USD. This estimate is not the same as the reported total societal cost of 163.81 USD since all the incremental differences in costs for each category and the final total cost estimate were estimated separately based on GLM models, which is responsible for the slight difference in costs. Additionally, the conversion of all log coefficients from the GLM models onto mean cost differences may also contribute to this difference. In the previous manuscript, the ICER estimate reported was the result of dividing the bootstrapped differences in costs by the differences In QALYs, however the actual difference estimates reported were not correct. All estimates have been updated following the new mapping, imputation of dataset and analysis. We now report cost and QALYs mean difference estimates resulting from the GLM models, both before and after bootstrapping, on table 3, pages 24-25, and in the results section, on page 12, lines 17-20 for mean difference in costs, and on page 13, lines 2-5 for mean difference in QALYs. The base-case ICER estimate with multiple imputation and following bootstrapping of cost and QALY differences is now ICER= =170.24/0.0031=54.916 USD reported both on table 4, page 26, in the results section, page 13, lines 16-17, and in the abstract on page 2.
11. Results page 12 line 12 the correct probability of cost effectiveness should be the proportion of replicates falling below the Swedish WTP threshold, not the proportion in the north eastern quadrant of the cost effectiveness plane. 14. Table 4 page 25 please add a column indicting the probability of cost effectiveness for each scenario A new column with all probabilities has been added to table 4 on page 26.
15. I am unable to comment on the discussion until the points of clarification in the methods and results are resolved.
We have rewritten the discussion to reflect the changes in analyses and findings in the present revision. We thank the reviewer for his comments and contribution to improving our work.
